A new oral vaccine targets colorectal cancer in two locations
This nanovaccine starts immune responses in the small intestine and boosts them at tumor sites.
Researchers developed a dual-site oral nanovaccine for colorectal cancer (CRC) immunotherapy. This vaccine uses a sequential immune cascade to fight tumors.
The nanovaccine is called DPML@OVA-CpG. It consists of mesoporous polydopamine nanoparticles loaded with antigen and CpG. These particles are stabilized by -glucan and plant-derived lipids.
The vaccine works by priming the immune system in the Peyer's patches of the small intestine. It then amplifies immunity at colorectal tumor sites. Near-infrared irradiation triggers immunogenic cell death of tumor cells. This process, along with locally released CpG, turns tumors into autologous in situ vaccine factories.
Oral vaccines face limits like inefficient mucosal delivery. They also lack spatiotemporal control over immune activation. This new strategy achieved therapeutic efficacy against liver metastatic CRC. It extended survival compared to PD-L1 antibody therapy and traditional single-site oral vaccination.
Key facts
- The DPML@OVA-CpG nanovaccine resists gastrointestinal degradation.
- The vaccine induces systemic effector and memory T cell responses.
- The strategy extends survival in liver metastatic CRC compared to PD-L1 antibody therapy.